Chlorambucil
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Chlorambucil: ALK-positive large B-cell lymphoma
One-Sentence Summary
Chlorambucil is an oral DNA-alkylating chemotherapy drug that has long been used in B-cell blood cancers. Evidence is thin: no registered clinical trials and 1 publication (a 2003 review that is not specific to this subtype) were found.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | ALK-positive large B-cell lymphoma |
| TxGNN Prediction Score | 0.9961 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Chlorambucil is a nitrogen mustard-type alkylating agent: it damages the DNA of rapidly dividing cells and can kill malignant lymphocytes. Alkylators have been used for many years against slowly growing B-cell cancers.
The predicted disease is a subtype of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), a mature B-cell cancer. Biologically, the link is plausible, and the prediction looks more like a refinement of a known disease group than a true shift to a new area.
There are important limits. The only retrieved publication is a 2003 Dutch-language review on risk-adapted management of CLL. It describes two CLL subtypes but gives no subtype-specific data on chlorambucil. It is a general review rather than a study of this disease, so the evidence level is held at L5. Modern practice also favours targeted agents (BTK inhibitors, venetoclax, anti-CD20 antibodies) over chlorambucil, especially in high-risk disease.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12577769 | 2003 | Review | Nederlands tijdschrift voor geneeskunde | CLL is the most common leukemia in the Western world and not truly indolent. Two subtypes exist (pre-germinal centre with unmutated immunoglobulin genes, and a post-germinal type), which supports a risk-adapted treatment approach. |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00004626 | LEUKERAN | Not recorded | Not recorded |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (alkylating agent, nitrogen mustard class) |
| Myelosuppression Risk | High. Bone marrow suppression (low white cells, platelets and red cells) is a recognised effect of this class |
| Emetogenicity Classification | Low to moderate |
| Monitoring Items | Complete blood count with differential, liver and renal function |
| Handling Protection | Follow cytotoxic drug handling regulations. Please refer to the package insert warnings and precautions |
Safety Considerations
- Conditions flagged as contraindicated or cautioned in drug-disease relationship data (not label text): thrombocytopenia, neutropenia, agranulocytosis, leukopenia, lymphopenia, anemia, interstitial lung disease, pulmonary fibrosis, drug-induced liver injury, nephrotic syndrome, epilepsy, and acute leukemias (including mixed phenotype acute leukemia).
- Drug Interactions: 100 interactions were recorded. Those classed as Major are:
- Deferiprone
- Samarium (153Sm) lexidronam
Moderate interactions include amphotericin B products, palifermin, strontium chloride Sr-89, mercaptopurine, roflumilast and chloramphenicol. Levofloxacin is minor. Others, such as prednisone, warfarin, omeprazole and simvastatin, are unclassified.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The model score is very high, but no trial or study directly examines chlorambucil in this subtype. The one publication is a general 2003 review, and current practice has largely moved to targeted therapies.
To proceed, the following is needed:
- Subtype-specific clinical data on chlorambucil, ideally comparison against current standard therapies
- Health Canada package insert warnings and contraindications, which are currently missing
- Mechanism-of-action data
- A review of how the hematologic and organ toxicities listed above apply to the target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.